WO2025022300 - AN ORODISPERSIBLE PHARMACEUTICAL SOLID DOSAGE FORM OF SAFINAMIDE
National phase entry:
Publication Number
WO/2025/022300
Publication Date
30.01.2025
International Application No.
PCT/IB2024/057099
International Filing Date
22.07.2024
Title **
[English]
AN ORODISPERSIBLE PHARMACEUTICAL SOLID DOSAGE FORM OF SAFINAMIDE
[French]
FORME POSOLOGIQUE SOLIDE PHARMACEUTIQUE ORODISPERSIBLE DE SAFINAMIDE
Applicants **
INTAS PHARMACEUTICALS LTD.
Inventors
PATEL, Manish
CHAUHAN, Manishkumar Jayantibhai
SEHGAL, Ashish
FORMOSA MÁRQUEZ, Xavier
Priority Data
202321050162
25.07.2023
IN
24179273.8
31.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2480 | |
| EPO | Filing, Examination, Granting | 12452 | |
| Japan | Filing, Examination, Granting | 2371 | |
| South Korea | Filing, Examination, Granting | 2544 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
24,987
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is related to the orodispersible pharmaceutical composition of safinamide comprising safinamide or its pharmaceutically acceptable salt thereof, ion exchange resin and one or more pharmaceutical acceptable excipients, wherein the said orodispersible pharmaceutical composition of safinamide is used for the treatment of Parkinson's disease.[French]
La présente invention concerne la composition pharmaceutique orodispersible de safinamide comprenant du safinamide ou son sel pharmaceutiquement acceptable, une résine échangeuse d'ions et un ou plusieurs excipients pharmaceutiquement acceptables, ladite composition pharmaceutique orodispersible de safinamide étant utilisée pour le traitement de la maladie de Parkinson.